LiDCO Group PLC
(“LiDCO” or the “Company”)
Posting of Annual Report and Notice of Annual General Meeting
LiDCO (AIM: LID), the hemodynamic monitoring company, announces that its Annual Report and Accounts for the year ended 31 January 2020 (the “Annual Report”) and Notice of the Annual General Meeting (“Notice of AGM”) are today being posted to all shareholders who had requested paper copies of those documents. All other shareholders will be sent the Notice of AGM and notification that the Annual Report will be published on the Company’s website at www.lidco.com/investors.
No form of proxy has been posted to shareholders, instead shareholders have been informed, in the documents sent today, that they will be able to vote electronically using the website www.signalshares.com or may request a paper proxy form directly from the registrars.
The Company will hold its AGM on Monday 1 June 2020 at 10.00 am. The Company considers the safety and wellbeing of both its shareholders and employees to be of paramount importance and with this in mind, the Company has made arrangements to comply with the current measures regarding restrictions on travel, limited gatherings and the ‘stay at home’ instructions introduced by the UK Government.
Only the Chairman of the meeting and one other person will attend the AGM thus fulfilling the requirement of the Company’s Articles of Association for a quorum to be present consisting of two persons entitled to vote upon the business to be transacted present in person or by proxy. Accordingly, other shareholders and proxies for shareholders will not be permitted to attend the AGM and shareholders are instead urged to submit electronic or paper proxy votes. Details on submitting proxy votes are contained in the Notice of AGM.
The results of voting on the resolutions at the AGM will be announced shortly afterwards and made available on the Company’s website.
The Board will continue to monitor COVID-19 developments as well as any further UK Government advice and will issue a further statement if the above arrangements require any amendment.
LiDCO Group Plc
Matt Sassone (CEO)
Tel: +44 (0)20 7749 1500
Tim Hall (CFO)
N+1 Singer (Nominated adviser and broker)
Tel: +44 (0)20 7496 3172
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Ltd
Tel: +44 20 7933 8780 or [email protected]
Mob: +44 7980 541 893
Mob: +44 7584 391 303
About LiDCO Group Plc (www.lidco.com)
LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO’s products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.
Increasingly clinical studies have shown that the optimisation of patients’ hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO’s computer-based technology, developed originally at St Thomas’ Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.
In critical care, LiDCO’s products have various in-built guided clinical protocols such as an end expiratory occlusion test (EEOT) and a tidal volume challenge (TVC), as a means to assess a patient’s fluid status. These methods have been referenced by key opinion leaders as an important part of the treatment pathway for ventilated patients with the Covid-19 coronavirus in critical care.
LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient’s changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient’s fluid and hemodynamic status – a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:
· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug
· quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic’s level of consciousness parameter (‘BISTM’)* and add the convenience of CNSystem’s continuous non-invasive blood pressure monitoring (‘CNAP’)**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.
*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.
**CNAPTM is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.
LiDCO’s headquarters are in London and its shares are traded on AIM.